No Data
No Data
Strong Buy Rating for Evolus Backed by Growth Potential and Market Penetration Prospects
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 101.19% HC Wainwright & Co. → $27 Reiterates Buy → Buy 05/08/2024 101.19% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Express News | Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months
Evolus Announces Positive Data From Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting
Evolus dermal filler, Evolysse Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity s
No Data